Class
Triple Agonist: GLP-1 / GIP / Glucagon
Half-life
~6 days
Purity
≥97% (HPLC)
Form
Lyophilized powder
Storage
2–8°C (refrigerated)
Reconstitution
Bacteriostatic water
Mechanism of action
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds a thermogenic effect — increased resting energy expenditure — on top of the appetite suppression and insulin secretion from GLP-1/GIP signaling. This triplicate approach hypothetically addresses obesity through three independent physiological mechanisms: appetite reduction, insulin sensitization, and direct fat mobilization via glucagon-stimulated lipolysis.
⚠️ For Research Use Only — described exclusively for in vitro and laboratory research by qualified researchers. Not for human or veterinary use. Informational only; does not constitute medical advice or imply efficacy in humans.
Research highlights
24.2%
Mean weight reduction at 12 mg (Phase 2, 48 wks)
3×
Receptor targets: GLP-1, GIP, glucagon
↑ EE
Increased resting energy expenditure (glucagon axis)
−40%
Reduction in liver fat (MRI-PDFF)
Research notes
- Phase 2 (NEJM 2023): 48-week trial showed 24.2% mean weight reduction at 12 mg — highest pharmacological weight loss data published at time of reporting.
- Glucagon thermogenesis: Distinct from dual agonists; direct increase in energy expenditure observed alongside caloric restriction.
- Liver fat: ~40% reduction in hepatic fat assessed by MRI-PDFF; significant implications for NASH research.
- Triglycerides: Marked reduction alongside visceral adipose tissue decrease.
- Tolerability: Dose-dependent GI side effects consistent with incretin class; Phase 3 now underway.
